US patents issued to Akaal Pharma on S1P1 receptor modulators useful for the treatment of autoimmune and inflammatory diseases
Several similar patent applications have been filed in Canada, Europe, Japan, China and India.
Akaal Pharma has announced that the United States Patent and Trademark Office (USPTO) has issued Akaal Pharma the US Patents 9,181,182 B2, and 9,193,716 B2, entitled S1P receptors modulators, and S1P receptors modulators and their use thereof, respectively.
The patents cover Akaal Pharma’s internally discovered various classes of novel compounds (small molecule drug candidates) as modulators of Sphingosine 1-Phosphate receptors (S1P) useful in the treatment of autoimmune and inflammatory diseases. Novel chemical scaffolds, synthetic intermediates and processes for the manufacture of drug candidates are claimed in these issued composition-of-matter patents. Several similar patent applications have been filed in Canada, Europe, Japan, China and India. Nearly 50 million people are afflicted with various autoimmune and inflammatory diseases in the US alone.
“These issued patents strengthen our patent position and expand further the intellectual property discovered internally by Akaal Pharma’s medicinal chemistry and drug discovery team. We believe that novel small molecules claimed in these patents could provide new generation of safer and more effective small molecule drugs for the treatment of autoimmune and inflammatory diseases including psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis, Crohn’s disease, stroke and others.” said Dale Dhanoa, CEO of Akaal Pharma.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.